Androgen deficiency in males

References

• Mulligan T, Frick MF, Zuraw QC et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int. J. Clin. Pract.60 (7), 762–769 (2006).
   PubMed Web of Science ®Google Scholar
• Schneider HJ, Sievers C, Klotsche J et al. Prevalence of low male testosterone levels in primary care in Germany: cross-sectional results from the DETECT study. Clin. Endocrinol.70(3), 446–454 (2009).
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham GC, Hayes FJ et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab.91, 1995–2010 (2006).
   PubMed Web of Science ®Google Scholar
• Anawalt BD. Chapter 22. In: Androgens in Health and Disease. Bagatell C, Bremner W (Eds). Humana Press, Totowa, NJ, USA 419–438 (2003).
   Google Scholar
• Tenover JL. Chapter 18. In: Androgens in Health and Disease. Bagatell C, Bremner W (Eds). Humana Press, NJ, USA 347–364 (2003).
   Google Scholar
• Wang C, Nieschlag E, Swerdloff RS et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male21(1), 1–8 (2009).
   Google Scholar
• Braunstein GD. Chapter 13. In: Basic and Clinical Endocrinology (8th Edition). Greenspan F (Ed.). Lange/McGraw-Hill, NY, USA 470–501 (2007).
   Google Scholar
• McPhee S, Lingappa VR, Ganong WF. Pathophysiology of Disease: an Introduction to Clinical Medicine (4th Edition). McGraw–Hill Companies, NY, USA 643 (2003).
   Google Scholar
• Harman SM, Metter EJ, Tobin JD, Person J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J. Clin. Endocrinol. Metab.86, 724–731 (2001).
   PubMed Web of Science ®Google Scholar
• Petak SM, Nankin HR, Spark RF et al. American association of clinical endocrinologists’ medical guidelines for clinical practice for the evaluation and treatment of Hypogonadism in adult male patients – 2002 update. Endocr. Pract.8(6), 439–456 (2002).
   Google Scholar
• Plymate SR. Chapter 3. In: Androgens in Health and Disease. Bagatell C, Bremner W (Eds). Humana Press, Totowa, NJ, USA 45–76 (2003).
   Google Scholar
• Bhasin S, Zhang, Coviello A et al. The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders. Steroids73, 1311–1317 (2008).
   PubMed Web of Science ®Google Scholar
• Morley JE, Charlton E, Patrick P et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism49, 1239–1262 (2000).
   PubMed Web of Science ®Google Scholar
• Corona G, Mannucci E, Petrone L et al. Association of hypogonadism and Type 2 diabetes in men attending an outpatient erectile dysfunction clinic. Int. J. Impot. Res.18, 190–197 (2006).
   PubMed Web of Science ®Google Scholar
• Tomar R, Dhindsa S, Chaudhuri et al. Contrasting testosterone concentrations in Type 1 and Type 2 diabetes. Diabetes Care29(5), 1120–1122 (2006).
   PubMed Web of Science ®Google Scholar
• Kapoor D, Maklin CJ, Channer KS et al. Androgens, insulin resistance and vascular disease in men. Clin. Endocrinol.63, 29–250 (2005).
   Google Scholar
• Kapoor D, Goodwin E, Channer KS et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with Type 2 diabetes. Eur. J. Endocrinol.154, 899–906 (2006).
   PubMed Web of Science ®Google Scholar
• Pitteloud N, Hardin M, Dwyer AA et al. Insulin resistance is association with a decrease in Leydig cell testosterone secretion in men. J. Clin. Endocrinol. Metab.90(5), 2636–2641 (2005).
   PubMed Web of Science ®Google Scholar
• Stellato RK, Feldman HA, Hamdy O et al. Testosterone, sex hormone-binding globulin and the development of Type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care23(4), 490–494 (2000).
   PubMed Web of Science ®Google Scholar
• Muller M, Grobbee DE, den Tonkelaar I et al. Endogenous sex hormones and metabolic syndrome in aging men. J. Clin. Endocrinol. Metab.90(5), 2618–2623 (2005).
   PubMed Web of Science ®Google Scholar
• Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with Type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male6, 1–7 (2003).
   PubMedGoogle Scholar
• Corrales JJ, Burgo RM, Garca-Berrocal B et al. Partial androgen deficiency in aging Type 2 diabetic men and its’ relationship to glycemic control. Metabolism53(5), 666–672 (2004).
   PubMed Web of Science ®Google Scholar
• Abate N, Haffner SM, Garg A et al. Sex steroid hormones, upper body obesity and insulin resistance. J. Clin. Endocrinol. Metab.87(10), 4522–4527 (2002).
   PubMed Web of Science ®Google Scholar
• Betancourt-Albrecht M, Cunningham G. Hypogonadism and diabetes. Int. J. Impot. Res.15(Suppl. 4), S14–S20 (2001).
   Google Scholar
• Gould DC, Kirby RS, Amoroso P. Hypoandrogen-metabolic syndrome: a potentially common and underdiagnosed condition in men. Int. J. Clin. Pract.61(2), 341–344 (2007).
   PubMed Web of Science ®Google Scholar
• Hayes FJ. Low testosterone tough on insulin sensitivity. Diabetes Forecast2, 63–67 (2007).
   Google Scholar
• Barrett-Connor E, Khaw KT, Yen SS. Endogenous sex hormone levels in older adult men with diabetes mellitus. Am. J. Epidemiol.132(5), 895–901 (1990).
   PubMed Web of Science ®Google Scholar
• Dhindsa S, Prabhakar S, Sethi M et al. Frequent occurrence of hypogonadotropic Hypogonadism in Type 2 diabetes. J. Clin. Endocrinol. Metab.89(11), 5462–5468 (2004).
   PubMed Web of Science ®Google Scholar
• Selvin E, Feinleib M, Zhang L et al. Androgens and diabetes in men. Diabetes Care30(2), 234–238 (2007).
   PubMed Web of Science ®Google Scholar
• Ding EL, Song Y, Malik VS et al. Sex differences of endogenous sex hormones and risk of Type 2 diabetes: a systematic review and meta-analysis. JAMA295(11), 1288–1299 (2006).
   PubMed Web of Science ®Google Scholar
• Chandel A, Dhindsa S, Topiwala S, Chaudhuri A, Dandona P. Testosterone concentration in young patients with diabetes. Diabetes Care31(10), 2013–2017 (2008).
   PubMed Web of Science ®Google Scholar
• Katzsnelson L. Chapter 13. In: Androgens in Health and Disease. Bagatell C, Bremner W (Eds). Humana Press, NJ, USA, 243–258 (2003).
   Google Scholar
• Dobs A. Androgen therapy in AIDS wasting. Baillieres Clin. Endocrinol. Metab.12(3), 379–390 (1998).
   PubMed Web of Science ®Google Scholar
• Grinspoon S. Androgen deficiency and HIV infection. Clin. Infect. Dis.41, 1804–1805 (2005).
   PubMed Web of Science ®Google Scholar
• Grinspoon S, Corcoran C, Askari H et al. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann. Int. Med.129, 18–26 (1998).
   PubMed Web of Science ®Google Scholar
• Bhasin S, Storer TW, Javanbakht M et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA283, 763–770 (2000).
   PubMed Web of Science ®Google Scholar
• Kenny AM, Raisz LG. Chapter 11. In: Androgens in Health and Disease. Bagatell C, Bremner W (Eds). Humana Press, NJ, USA, 221–232 (2003).
   Google Scholar
• Benito M, Vasilic B, Wehrli FW et al. Effect of testosterone replacement on trabecular architecture in hypogonadal men. J. Bone Miner. Res.20(10), 1785–1791 (2005).
   PubMed Web of Science ®Google Scholar
• Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med.357(9), 905–916 (2007).
   PubMed Web of Science ®Google Scholar
• Amory JK, Watts NB, Easley KA et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J. Clin. Endocrinol. Metab.89, 503–510 (2004).
   PubMed Web of Science ®Google Scholar
• Snyder PJ, Peachey H, Hannoush P et al. Effect of testosterone on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab.84, 1966–1972 (1999).
   PubMed Web of Science ®Google Scholar
• Ohl DA, Quallich SA. Clinical hypogonadism and androgen replacement therapy: an overview. Urol. Nurs.26(4), 243–260 (2004).
   Google Scholar
• Leichtnam ML, Rolland H, Wuthrich P et al. Testosterone hormone replacement therapy: state-of-the-art and emerging technologies. Pharm. Res.23(6), 1116–1132 (2006).
   Google Scholar
• Margo K, Winn R. Testosterone treatments: why, when and how? Am. Fam. Physician73(9), 1591–1598 (2006).
   PubMed Web of Science ®Google Scholar
• Cunningham GR. Testosterone replacement therapy for late-onset hypogonadism. Nat. Clin. Pract. Urol.3(5), 260–267 (2006).
   PubMedGoogle Scholar
• AndroGel® 1% CIII, package insert. Solvay Pharmaceuticals, Inc., GA, USA.
   Google Scholar
• Testim® 1%, package insert. Auxillium Pharmaceuticals, Inc., PA, USA.
   Google Scholar
• Striant ™, package insert. Columbia Laboratories Inc., NJ, USA.
   Google Scholar
• Androderm®, package insert. Watson Pharmaceuticals, Inc., CA, USA.
   Google Scholar
• Kaminetsky JC. Benefits of a new Testosterone gel formulation for hypogonadal men. Clin. Cornerstone7(Suppl. 4), S8–S12 (2005).
   PubMedGoogle Scholar
• Boehringer SK. Comparison of testosterone replacement products. In: Pharmacist’s Letter/Prescriber’s Letter. Therapeutic Research Center, CA, USA, 19(190803), 1–4 (2003).
   Google Scholar
• Cunningham GR. Male hypogonadism; management strategies. News & views on male testosterone deficiency. Renal Urology News1(3), supplement (2006).
   Google Scholar
• Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring (review). N. Engl. J. Med.350(50), 482–492 (2004).
   PubMed Web of Science ®Google Scholar
• Karpman E, Lipshultz LI, Williams DH. The therapeutic challenges of hypogonadism and its comorbidities. First Report. March (2006).
   Google Scholar
• Kalyani RR, Gavini S, Dobs AS. Male hypogonadism in systemic disease. Endocrinol. Metab. Clin. North Am.36(6), 333–348 (2007).
   PubMed Web of Science ®Google Scholar
• Ding EI, Song Y, Manson JE et al. Sex hormone-binding globulin and risk of Type 2 diabetes in women and men. NEJM DOI: 10.1056/NEJMoa0804381 (2009).
   Google Scholar
• Guay AT. The emerging link between hypogonadism and metabolic syndrome. J. Androl.30(4), 370–376 (2009).
   PubMedGoogle Scholar
• Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J. Androl.30, 10–22 (2009).
   PubMed Web of Science ®Google Scholar
• Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J. Androl.30, 23–32 (2009).
   PubMedGoogle Scholar